1 GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group
2 Common Misconception
3 Good Laboratory Practices 1) A quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported. 2) GLPs are regulations published in the Code of Federal Regulations (21CFR part 58) 3) The OECD Principles of Good Laboratory Practice 4) GLPs are not guidelines, they have the force of law. 5) GLP s are not watered down GMPs!
4 Good Manufacturing Processes 1) Good manufacturing practice is the part of quality assurance which ensures that products are consistently produced and controlled to the quality standard appropriate to their intended use and as required by the Marketing Authorization or product specification. 2) GMP is concerned with both production and quality control 3) The rules Governing Medicinal Products in the EU; Volume 4 EU Guidelines to GMP Medicinal products for human and veterinary use
5 Good Clinical Practice 1) GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects. 2) Compliance with this standard provides public assurance that the rights, safety, and well being of trial subjects are protected, consistent with the principles that hve their origin in the Declaration of Helsinki, and that the clinical data are credible. 4) Guideline for Good Clinical Practice ICH Harmonization Triparite Guideline
6 FDA GLP Regulations Apply to (58.1) Non-clinical laboratory studies that support or are intended to support application for research or marketing permits for the following products: food and color additives human and animal drugs medical devices for human use biological products electronic products GLPs have nothing to do with manufacturing product!
7 Non-clinical Laboratory Studies (58.3) In vitro or in vivo experiments in which test articles are studied prospectively in test systems under laboratory conditions to determine their safety. The term does not include studies utilizing human subjects or clinical studies or field trials in animals. The term does not include basic exploratory studies carried out to determine whether a test article has any potential utility or to determine the physical or chemical characteristics of a test article.
8 Basic Elements of GLP Personnel Documents - Sponsor - Standard Operating - Management - Protocols - Study Director - Reports - Quality Assurance - Archiving Facility Test and Control Articles - Laboratory Operation - Characterization - Animal care - Handling - Equipment - Storage - Reagents -Storage
9 Main Responsibilities Function GLP GMP GCP Ownership Facility Management Manufaturer Sponsor Main responsibility for the activity Responsibility for Production Study Director Qualified Person Principal Investigator Principal Investigator Head of Production Pharmacist Quality Quality Assurance Head of Quality Assurance/Quali ty Control Monitor/Quality Assurance Archive Archivist Archivist
10 Sponsor (58.3) Sponsor means: a person who initiates and supports, by provision of financial or other resources, a non-clinical laboratory study a person who submits a non-clinical study to the FDA in support of an Application for a research or marketing permit a testing facility, if it both initiates and actually conducts the study
11 Management Responsibilities (58.31) Designate a Study Director before the study is initiated Replace the Study Director promptly, if necessary Assure that there is a Quality Assurance Unit Assure that the test and control article have been appropriately tested for identity, strength, purity, stability and uniformity, as applicable Authorize significant changes in SOPs Assures that any deviation from GLP regulations reported by the quality assurance unit are communicated to the Study Director and corrective actions are taken and documented
12 Study Director (58.33) For each non-clinical laboratory study, a scientist or other professional of appropriate education, training and experience, or combination thereof, shall be identified as Study Director.
13 Study Directors Only one person is designated as Study Director There cannot be a co-study Director There can be an alternate Study Director There is no requirement for a Study Director in GMPs The GCPs require a Principal Investigator
14 Quality Assurance Unit (58.35) A testing facility shall have a Quality Assurance unit which shall be responsible for monitoring each study to assure management that the facilities, equipment, personnel, methods, practices, records, and controls are in conformance with the regulations. For any given study, the Quality Assurance unit shall be entirely separate from and independent of the personnel engaged in the direction and conduct of the study.
15 QAU Responsibilities (58.35 (b)(1) Maintain a copy of a master schedule sheet of all non-clinical studies conducted at the testing facility indexed by: test article test system nature of the study date study was initiated current status of study Sponsor Study Director 15
16 QAU Responsibilities (Cont.) Maintain copies of all protocols Inspect each non-clinical study at adequate intervals Maintain signed records of each inspection date of inspection study inspected phase inspected person performing the inspection findings recommendations
17 Overall QAU Responsibilities There are 3 things the Quality Assurance Unit is responsible for verifying: 1) Is the Study being conducted in accordance with the protocol 2) Is the Study being conducted in accordance with relevant SOPs 3) Is the Study being conducted in accordance with the GLP regulations
18 Role of the QA unit QA reviews SOPs for compliance with GLPs QA does not approve SOPs (in a GLP environment) GLPs do not require that QA sign SOPs (It is an industry standard) QA is responsible for assuring Management that working procedures comply with the SOPs QA is responsible for reporting deviations to Study Directors and to Management
19 Facilities GLPs do not require any facility validation There is no requirement for air classification There is no specific requirement for room sanitization (in vitro studies) There is no specific requirement for plumbing, welding,
20 Equipment Requirements For each piece of equipment you must have: an equipment notebook an SOP on operation an SOP on calibration and maintenance GLPs do not require formal IQ, OQ, PQ processes
21 21 CFR Part A testing facility shall have standard operating procedures in writing setting forth non-clinical laboratory study methods that Management is satisfied are adequate to insure the quality and integrity of the data generated in the course of a study.
22 21 CFR Part Each laboratory area shall have immediately available laboratory manuals and standard operating procedures relative to the laboratory procedures being performed. Published literature may be used as a supplement to standard operating procedures. A historical file of standard operating procedures, and all revisions thereof, including the dates of such revisions, shall be maintained.
23 QA and SOPs QA doesn t write all SOPs, only those that are directly related to QA functions QA reviews SOPs for compliance with GLPs QA does not approve SOPs (in a GLP environment) GLPs do not require that QA sign SOPs QA is responsible for assuring Management that working procedures comply with the SOPs QA is responsible for reporting deviations to Study Directors and to Management
24 Management of SOPs GLP GMP GCP QA does not approve SOPs QA reviews SOPs for GLP compliance only QA approves SOPs The historical file and original copies are filed by QA The Sponsor has the responsibility for the SOP system SOP management is under the QAU but is the responsibility of Management The whole SOP documentaton system is under QA QA helps in the drafting of the SOPs
25 21 CFR Part Each study shall have an approved written protocol that clearly indicates the objectives and all the methods for the conduct of the study. Protocols do not contain fill in the blanks ; they are stand alone documents. There are no batch records in GLPs OECD: Study Plan
26 GLP pecking order GLP regs > Protocol > SOPs GLP regs supercede the protocol and the SOPs The protocol always supercedes the SOPs
27 Protocol Amendments All changes in or revisions of an approved protocol and the reasons therefor shall be documented, signed by the Study Director and maintained with the protocol. Protocol amendments are intended to document permanent changes If a deviation from the protocol is an error, it should not result in a protocol amendment (GLPs do not require investigations) If possible, protocol amendments should be prospective If possible, a protocol amendment should be distributed before the change is intended to occur (that includes QA).
28 Final Reports: A final report shall be prepared for each nonclinical laboratory study and shall include, but not be limited to, the following: name and address of the facility performing the study dates on which the study was initiated and completed date the study director signed the protocol date the study director signed the final report
29 Final reports: A description of all circumstances that may have affected the quality or integrity of the data report all protocol and GLP deviations the Study Director then makes a judgement as to whether these deviations had an impact on the quality or integrity of the data This is done in the form of a Compliance Statement Compliance statements are signed by the Study Director not by QA
30 GLP Compliance statement Sterling Biotech Research Facility Protocol No Safety Testing in hamsters of a New Vaccine Candidate (R1009) for Contagious Jungle Rot This study was conducted at the Sterling Biotech Research facility (SBRF) in compliance with the U.S. Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58) and applicable Standard Operating Procedures except as noted in the report or raw data: Study Director: Date:
31 A Quality Assurance Statement Study title: Quality Assurance Statement The Greatest Research Center Protocol No.: Quality Assurance inspections of the study and review of the final report of the above referenced study were conducted according to the procedures described in the standard operating procedures of the Quality Assurance unit and according to the general requirements of the Good laboratory Practice Regulations, 21CFR, part 58, as issued by the FDA. Findings from the inspections and the final report review were reported to the Study Director and the management on the following dates: Inspection/reviews Findings Reported (Date) Auditor - -
32 Archiving In a GLP environment, the FDA can and will audit your archive. Inspectors will physically go where your documents are archived In a GMP environment the FDA is not known to audit archiving facilities
33 None of these apply to GLPs
34 Retention of Records: 21CFR part FDA Documentation records, raw data and specimens pertaining to a non-clinical laboratory study shall be retained in the archive(s) for which ever period is the shortest: 1) A period of at least 2 years following the date on which an application for a research or marketing permit, in support of which the results of the non-clinical laboratory study were submitted, is approved by the FDA 2) A period of at least 5 years following the date on which the results of the non-clinical laboratory study are submitted to the FDA in support of an application for a research or marketing permit.
35 FDA inspections In the US there is no means by which you can request a GLP inspection In the US there is no GLP certification program similar to the ISO certifications Submission of data to the regulatory authorities is what triggers a GLP inspection
36 Four Kinds of FDA Inspections 1) GLP inspection: periodic routine determination of a laboratory s compliance with GLPs (usually includes an ongoing study as well as as a completed study). Scheduled once every two years. 2) Data audit: an inspection made to verify that the information contained in a final report submitted to the FDA is accurate and reflected by the raw data. 3) A directed inspection (or for cause inspection): inspections conducted for various compelling reasons (questionable data in a final report, tips from informers, etc...). 4) A follow-up inspection: an inspection made sometime after a GLP inspection which revealed objectionable practices and conditions. The purpose of a follow up inspection is to assure that proper corrective actions have been taken.
37 What the FDA can do to you Warning letter (these are posted on the internet: Re-inspection Informal conference Third party validation of a non-clinical study Disqualification of the facility Injunction/Prosecution Withholding or revocation of Marketing Permit Termination of an IND
38 Conclusion There is no such thing as GLP lots GLPs do not apply to manufacturing anything Product manufactured for toxicology studies must be tested for safety. These in vitro and in vivo tests must be conducted in compliance with GLPs There is no such thing as GCP lots Clinical material must be tested for safety and efficacy in humans. These tests in humans must abide by GCPs
39 GLP, GMP and GCP activities can overlap
40 This many people working for a year to make this much drug!
Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP Document issued on: June 2004 U.S. Department of Health and Human Services Food and Drug Administration
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace
The Concept of Quality in Clinical Research Dorota Śwituła Senior Clinical Quality Assurance Advisor 1 Agenda What is quality? How we define quality in clinical research? The standard components of a Quality
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
Regulatory Submission: Applying GLP in Surgical Efficacy Studies Curtis Schondelmeyer, DVM Director Preclinical Veterinary Services and Efficacy and Surgical Research Services Welcome to Toxikon 2 CONFIDENTIAL
Standards for Laboratory Facilities Version 2.1 APPROVED 24 FEBRUARY 2014 Article I. General Provisions Section 1.01 The facility shall be of suitable size and construction to facilitate the proper conduct
CGMP for Phase 1 Clinical Trials Harvey M. Arbit, PharmD, MBA, RAC, CCRP University of Minnesota Academic Health Center Director, IND/IDE Assistance Program Lead, Regulatory Knowledge and Support Clinical
Page 1 of 8 The Royal Veterinary College Introduction Preface Good Research Practice Funding bodies need to be assured of the quality and validity of research they fund and ensure their contractors are
Chapter 48 Bioresearch Monitoring Subject GOOD LABORATORY PRACTICE (Nonclinical Laboratories) Implementation Date February 21, 2001 Completion Date Continuing Product Codes 51Z or 52Z 45Z, 46Z 57Z, 99Z
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry Version March 2015 QUESTIONS
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health
LIBRARY GUIDE: Clinical Pharmaceutical Table of Contents Overview...2 Course Descriptions Core Knowledge: A Tour of the FDA (PHDV60)...4 A Tour of Health Canada (PHDV89)...4 A Tour of Health Europe (PHDV90)...4
IVT 9 th Annual Conference Change Control Change Control A Key Element of a Quality System Jerry Lanese Ph.D. CMC The Lanese Group, Inc. 2011 The Lanese Group 1 Will discuss A Quality System What is it
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)
Good Clinical Practice 101: An Introduction Presented by: Lester Jao Lacorte, MD Medical Officer Commissioner s Fellow Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
contract research expertise TECHNICAL PAPER GLP vs. non-glp: A Practical Applicaton Comparing required elements in a GLP-compliant and non-glp study 2 GLP vs. non-glp: A Practical Application Abstract...
Sponsor Audits of Bioanalytical Laboratories One of the critical tasks for a Good Laboratory Practices (GLP) nonclinical laboratory study or Clinical Trial team is choosing a bioanalytical laboratory vendor
Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials Vanessa Grant and Tim Stiles VERSION 2 Published by
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. firstname.lastname@example.org Overview GMP requirements for Quality Control laboratories
Document CEN TC 258/WG2 N15 (Draft # 6, June 2000) CEN TC 258 Committee Enquiry/ISO TC 194 Committee Draft EN ISO 14155 CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN SUBJECTS PART 2: CLINICAL INVESTIGATION
OECD and US GLP Applications Del W. Huntsinger BASF, Reserach Triangle Park, USA email@example.com Agenda Brief Overview US GLPs OECD GLPS Similarities Differences Looking Forward OECD and US GLP
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good
Integrating Good Manufacturing Practices During the Transition from Clinical Trials to Commercial Manufacturing By Mark Zemler W H I T E P A P E R Executive Summary In support of our customers, this whitepaper
Inspected site(s): Activities Carried out: GMP Inspection report Manufacture of Active Substance Manufacture of Finished Medicinal Product Packaging Importing Laboratory Testing Batch Control and Batch
Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management
IVTGXP_july06.qxd 6/28/06 1:09 PM Page 36 Computerized System Audits In A GCP Pharmaceutical Laboratory Environment By Maintaining data integrity for both clinical laboratory processes and patient data
HOW TO DEAL IN A REGULATED ENVIRONMENT Matt Rigerman Director Operations & Quality Reichert, Inc. CMQ/OE, CSSBB, CQA AGENDA Origin of the FDA Medical Devices standard (21 CFR 820) Compliance strengthens
Organization of QA cgmp compliance BIT 230 Chapters 1 and 2 (Huxsoll) TQM Total Quality Management Approach a company uses day to day 7 strategies Leadership Information and analysis Strategic planning
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: SOP number: SOP category: Document Control GE-003 General SOP history Version number: 01 Version date: 1 March 2013 Effective
Laboratory Notebooks. As scientists we understand the value of maintaining quality laboratory notebooks. Notebooks are daily records of every experiment you do or that you are planning to do. Notebooks
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special
INTRODUCTION This book offers a systematic, ten-step approach, from the decision to validate to the assessment of the validation outcome, for validating configurable off-the-shelf (COTS) computer software
1 of 11 1. Introduction The International Safe Transit Association (ISTA), a non-profit association whose objective is to prevent product damage and excess packaging usage within the distribution environment.
STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA SOP#: 010.17 Date Issued: 5/99 Date Revised: 3/16 Page 1 of 5 TITLE: SCOPE: RESPONSIBILITY: PURPOSE: All Animal
The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute
Regulatory oversight of drug clinical trial in China Wang Jianan CFDI-CFDA firstname.lastname@example.org 2014.9,Berlin 1 Outline Brief introduction of CFDA/CFDI Relevant laws and regulations Supervision of drug clinical
APEC Preliminary Workshop: Review of Drug Development in Clinical Trials Session 1.4 -Clinical Trial Environment United States (FDA) and European Union (EMEA) Susan D Amico Vice President and Global Head
British Association of Research Quality Assurance DISCUSSION PAPER NUMBER 6 IN A SERIES PRODUCED BY THE GLP COMMITTEE THE APPLICATION OF GLP PRINCIPLES TO FIELD STUDIES REPORTING AND ARCHIVING Author(s)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
FDA Regulation of Medical Devices Bradley Merrill Thompson Interpharm Press, Inc. Buffalo Grove, IL Dedication Acknowledgments Introduction xv xvi xvii Part I. Overview Chapter 1. The History of Medical
Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA This presentation is the property of DynPort Vaccine Company LLC, a CSC company, and
CNE Disclosures Successful Completion: Participants must complete an evaluation form to receive a certificate of completion Contact Hours: 1 contact hour is available to those who meet the successful completion
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
GMP Training Course Quality Control 20-21 October 2009 Lesley Graham Senior Inspector (UK) Quality Control GMP in the QC Laboratory Certificates of Analysis Dealing with out of specification results Parametric
This English translation of ordinance on GLP has been made by JSQA. JSQA translated them with particular care to accuracy, but does not guarantee that there are no differences in the delicate shades of
From paper to electronic data Bioindustrypark, October 10, 2013 Dr Alessandra Grande Ivrea GxP Test Facility QA Manager, Head Global BMT QA Research & Development Quality Assurance MerckSerono RBM Outline
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité New Investigator Collaborations and Interactions: Regulatory NCIC Clinical Trials Group New Investigator Clinical Trials
Guidance for Industry Computerized Systems Used in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration (FDA) Office of the Commissioner (OC) May 2007 Guidance
PHT. 463- (Quality Control of Pharmaceutical Dosage Forms) Midterm Exam I Dr. Ibrahim A. Alsarra s Section Part I Read the Questions Carefully TRUE OR FALSE: Indicate whether the statement is true or false
Data Quality and the Origin of ALCOA Stan W. Woollen Senior Compliance Advisor Stan Woollen and Associates If one does a Google search on the term ALCOA, virtually all of the hits lead to Alcoa Inc. According
White paper: FDA Guidance for Industry Update Process Validation In January 2011, the FDA released the final version of its long-awaited update to its Process Validation Guidance for Industry. Since then,
L1 2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager,
Questionnaire for preparing GMP-inspections Questionnaire for preparing GMP-inspections Dr. Christine Oechslein, Max Lazar, Thomas Halfmann Here you will find answers to the following questions: What questions
Regulator s Role in GCP David A. Lepay, M.D., Ph.D. APEC GCP Inspection Workshop May 27, 2008 Objectives of this Talk Review the roles and responsibilities of the regulatory authority under GCP Identify
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program Part 2 GCP Information Sessions November 2010 Inspection Program Main objectives
The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010
How to Manage Regulatory Issues and get FDA Approvals Maureen Garner, President Glenn Neuman, Director of Scientific Affairs New World Regulatory Solutions, Inc. www.newworldreg.com 1 About NWRS New World
REGULATORY AND ETHICAL REQUIREMENTS FOR HERBAL MEDICINE Hary Wahyu T. National Agency of Drug and Food Control Republic of Indonesia 13 TH FERCAP International Conference Sanur Beach Hotel, Sanur, Bali
RAC (US) Examination Study Checklist Instructions: Use this checklist to track your progress when preparing for the RAC (US) certification examination. When you begin your studying, each task statement
TITOLO SLIDE Testo Slide Testo Slide Testo Slide Clinical database/ecrf validation: effective processes and procedures IV BIAS ANNUAL CONGRESS Padova September, 26 th 2012 PQE WORKSHOP: What's new in Computerized
Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Alex D. Kanarek, PhD BioProcess Technology Consultants, Inc. Strategic Institute Quality
Global Good Manufacturing Practice A Comparability Study to Link Good Manufacturing Practice Standards for World Wide Compliance Within the Cellular Therapy Industry Presented by Rosemarie Bell 24 April
Clinical Investigator Training Course Investigator Responsibilities in Biomedical Research Covered by FDA Regulations Lisa Zimmerman Objectives Discuss Clinical Investigator Obligations according to FDA
Current Good Manufacturing Practice for PET Drugs - CGMP 21 CFR 212 CDER Office of Regulatory Policy Jane Axelrad, JD CDER Office of Compliance Brenda Uratani, Ph.D. CDER ONDQA Ravindra Kasliwal, Ph.D.
Personal Data Name Title Validation Consultant Contact jsb-validierung Zwischen den Bächen 9 D 79618 Rheinfelden Tel: +49 7623 79 49 82 Mobile: +49 172 737 84 86 E-Mail: Internet: email@example.com http://www.jsb-validierung.de
TABLE OF CONTENTS Acknowledgments... xi Introduction... xiii 1 The Clinical Research Coordinator (CRC)... 1 Background and Training of the CRC...1 Personality and Skills... 2 Where Do CRCs Work?... 2 CRC
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
INTERPLANT STANDARD - STEEL INDUSTRY IPSS SPECIFICATION & GUIDE FOR CALIBRATION SYSTEM OF INSTRUMENTATION No Corresponding IS IPSS: 2-07-098-14 0. FOREWARD 0.1. Interplant standardization: Standardization
Establishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs) Cornelia Kamp, MBA Executive Director Strategic Initiatives Tim Hackett Director
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
BME 695 November 8, 2011 Engineering Nanomedical Systems Lecture 15 GMP and issues of quality control manufacture of nanodelivery systems James F. Leary, Ph.D. SVM Endowed Professor of Nanomedicine Professor
Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for
IMP management at site Dmitry Semenyuta TOP 5 FDA inspections finding 1999-2009 Center of Drug Evaluation and Research (CDER) Failure to follow the protocol Failure to keep adequate and accurate records
Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.